[18] Other research suggests that several pharmaceutical companies, including AstraZeneca, Zealand Pharma, Roche, and Amgen, are expected to enter the GLP-1 market, with multiple drug launches planned between 2027 and 2032
Together, these therapies form a comprehensive pharmacologic toolbox that can be tailored to each patients needs
This usually necessitates a specific clinical trial design, which is a major cost driver but also a source of new, defensible IP
To put that in perspective, people on the highest dose of tirzepatide (15 mg) lost about 25 pounds on average, while those on the highest dose of semaglutide (1 mg) lost about 13 pounds
Wake up in the morning and take your fruits and vegetables